Stock Performance and Market Context
On 19 August 2026, Parmax Pharma Ltd’s stock opened at Rs.124.95, registering a 2.00% gain on the day and outperforming its sector by 1.81%. The stock maintained this price throughout the trading session, closing at its intraday high. This price level represents a new 52-week and all-time high, surpassing the previous peak and setting a fresh benchmark for the company’s market valuation.
The stock has demonstrated a robust upward trajectory, gaining consecutively for 11 trading sessions and delivering a cumulative return of 24.14% during this period. This momentum is further underscored by the stock’s performance relative to the broader market indices. Over the past day, Parmax Pharma advanced by 2.00%, while the Sensex declined by 0.40%. The stock’s outperformance extends across multiple time frames:
- One week: +10.38% versus Sensex -1.33%
- One month: +23.82% versus Sensex -1.56%
- Three months: +296.67% versus Sensex +2.30%
- One year: +230.12% versus Sensex -5.78%
- Year-to-date: +269.35% versus Sensex -9.73%
- Three years: +323.56% versus Sensex +18.45%
- Five years: +230.12% versus Sensex +38.29%
This exceptional relative performance highlights the stock’s strong recovery and growth compared to the broader market and sector peers.
Technical Indicators and Trend Analysis
The technical outlook for Parmax Pharma Ltd remains firmly bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum. The overall technical trend shifted to bullish on 7 August 2026 when the stock crossed the Rs.106.75 level, confirming a positive change from a previously mildly bullish stance.
Key technical indicators reinforce this trend:
- MACD: Bullish on both weekly and monthly charts
- Bollinger Bands: Bullish on weekly and monthly timeframes
- KST (Know Sure Thing): Bullish weekly and monthly
- Dow Theory: Bullish on both weekly and monthly
- RSI: Bearish on monthly, indicating some caution overbought conditions in longer term
Immediate support is established at the 52-week low of Rs.22.60, while the stock has surpassed major resistance levels at Rs.47.40 (200 DMA), Rs.62.09 (100 DMA), and Rs.108.69 (20 DMA). The current price of Rs.124.95 represents a strong resistance breakout, confirming the stock’s upward strength.
Valuation and Financial Metrics
Despite the impressive price performance, Parmax Pharma Ltd remains a loss-making entity on a trailing twelve months (TTM) basis, with the price-to-earnings (P/E) ratio not applicable. The company’s valuation multiples reflect this status, with negative figures for price-to-book value (-7.45x), EV/EBITDA (-22.68x), and EV/EBIT (-15.08x). The EV/Sales multiple stands at 3.08x, while EV/Capital Employed is 12.01x.
Dividend metrics are not applicable as the company has not declared dividends, maintaining a zero payout ratio. The absence of dividend yield aligns with the company’s reinvestment and growth focus.
The 52-week price range spans from Rs.22.60 to Rs.124.95, with the current price exactly at the high end, representing a 452.88% increase from the low point within the year.
Quality and Financial Trend Assessment
Parmax Pharma Ltd’s overall quality grade is classified as below average, reflecting challenges in long-term financial performance. Key quality indicators include below average management risk, growth, and capital structure. The company has experienced a 5-year sales decline of 6.45% and a significant 213.12% decrease in EBIT over the same period. Average EBIT to interest coverage is weak at 0.66x, though the company benefits from a net cash position with negative net debt to equity of -1.77, indicating minimal leverage.
Other quality factors include a tax ratio of 100%, no promoter share pledging, and low institutional holdings. Return on capital employed (ROCE) and return on equity (ROE) remain weak at -28.89% and 5.12% respectively.
Short-term financial trends show positive momentum as of June 2026, with net sales for the latest six months growing by 70.31% to ₹11.53 crores. Quarterly profit before depreciation, interest, and tax (PBDIT) reached a high of ₹0.83 crores, while profit before tax less other income (PBT less OI) and profit after tax (PAT) also hit quarterly highs of ₹0.12 crores and ₹2.20 crores respectively. Earnings per share (EPS) for the quarter stood at ₹5.88, the highest recorded.
However, some caution is warranted as the debtors turnover ratio for the half year is at a low of 3.83 times, and non-operating income constitutes 94.55% of profit before tax, indicating reliance on non-core income sources.
Delivery Volumes and Market Activity
Recent delivery volumes have surged significantly, with a 1-month delivery change of 148.31% and a 1-day delivery change of 69.09% compared to the 5-day average. On 18 August 2026, the volume was 257 shares, representing 100% of total volume for the day. The trailing one-month average volume stands at 25,170 shares, more than doubling the previous month’s average of 10,140 shares, signalling increased trading interest and liquidity.
Mojo Score and Market Rating
According to MarketsMOJO, Parmax Pharma Ltd holds a Mojo Score of 46.0 with a current Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 10 August 2026. The stock is classified within the Pharmaceuticals & Biotechnology thematic list, reflecting its sector affiliation. The micro-cap market capitalisation grade further contextualises the company’s size and market presence.
Summary
Parmax Pharma Ltd’s stock reaching an all-time high of Rs.124.95 on 19 August 2026 marks a significant milestone in its market journey. The stock’s strong performance over multiple time frames, combined with a bullish technical outlook and improving short-term financial trends, underscores the company’s recent market strength. While valuation metrics and quality assessments indicate areas for improvement, the stock’s sustained gains and breakout above key resistance levels highlight a noteworthy phase in its trading history.
